In conclusion, this study demonstrates an excellent DBP predictive capacity for ALK inhibitors cytotoxicity, which is feasible because ALK-TKIs induce a rapid increase of the activator BIM in cell lines and patient-derived tumor cells, fostering the employment of this functional assay in a clinical setting. This evidence concerns the gene ALK and neoplasm.